Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna plans to trim roughly 10% of its global workforce by the end of the year to cut costs amid declining sales of its COVID-19 vaccines, the company said on Thursday.

Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

Moderna is set to slash ten percent of its workforce this year, the pharmaceutical giant revealed on Thursday morning. The ...

The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

RSV vaccines are 82% effective for older people and 72% for newborns when mothers are vaccinated at least 14 days before ...

As federal vaccine policy shifts under US health secretary Robert F. Kennedy Jr., lawmakers are looking to give state-level ...